This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pipracil

Pfizer Inc.

Drug Names(s): Piperacillin sodium

Description: Pipracil (Piperacillin) is a penicillin derivative of the anti-pseudomonal penicillin class. These agents offer significant activity against Pseudomonas aeruginosa, a common cause of hospital acquired infections whose cell wall naturally confers resistance to many antibiotics. Antipseudomonal penicillins are susceptible to beta lactamases, and are therefore poorly active against Staphylococci and enteric gram negative bacilli. They retain the activity of natural penicillins against streptococci and enterococci.

Deal Structure: Pipracil was originally developed by Wyeth.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.


Pipracil News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug